Investigating Participation Patterns Among Stage IV Melanoma Patients
Study Details
Study Description
Brief Summary
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.
The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of stage IV melanoma patients who decide to enroll in a clinical research [3 months]
- Rate of stage IV melanoma patients who remain in clinical trial to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged ≥ 18 years old
-
Diagnosis of stage IV melanoma
-
Able to comprehend the investigational nature of the protocol and provide informed consent
Exclusion Criteria:
-
Female patients who are currently pregnant or nursing
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
-
Inability to perform regular electronic reporting
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Power Life Sciences | San Francisco | California | United States | 94107 |
Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Luen S, Wong SW, Mar V, Kelly JW, McLean C, McArthur GA, Haydon A. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. Am J Clin Oncol. 2018 Jan;41(1):90-94. doi: 10.1097/COC.0000000000000226.
- Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014. J Am Acad Dermatol. 2018 Aug;79(2):258-265.e4. doi: 10.1016/j.jaad.2018.03.021. Epub 2018 Mar 23.
- Wevers KP, Hoekstra HJ. Stage IV melanoma: completely resectable patients are scarce. Ann Surg Oncol. 2013 Jul;20(7):2352-6. doi: 10.1245/s10434-013-2881-1. Epub 2013 Feb 8.
- 74815433